The first study in the UK to directly compare immune reactions between Pfizer's and AstraZeneca's COVID-19 vaccines has found strong and broadly similar antibody responses in people aged over 80 after a first dose of either shot, Reuters news agency revealed on Wednesday.
The study analysed blood samples from 165 people in Britain aged between 80 and 99 who had been given a first COVID-19 vaccine dose.
Scientists who carried out the study also found that T cells, a critical component of the immune system, showed a more enhanced response in those who received the AstraZeneca/Oxford University vaccine compared to those who were given the Pfizer/BioNTech vaccine. The scientists believe that these findings merit further investigation.
Reuters added that this study was published online as a preprint before being peer reviewed. It found that key antibodies were present and at similar levels in 93% of the 76 study participants who were given the Pfizer single COVID-19 vaccine dose and 87% of the 89 participants who received the AstraZeneca shot.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma